by Barry101 | Dec 12, 2024 | Press Release
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM’s View, the Activist Group’s...
by Barry101 | Dec 12, 2024 | Press Release
OCALA, Fla., Dec. 12, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 – a compositions and...
by Barry101 | Dec 10, 2024 | Press Release
Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Conclude That Activist Group’s Plan Lacks Detail and Does Not Justify Control of the Board ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd...
by Barry101 | Dec 6, 2024 | Press Release
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced...
by Barry101 | Dec 5, 2024 | Press Release
ISS Finds That Activist Group’s Plan is “Limited” and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini “Does Not Appear to Be an Appropriate Choice for the AIM Board” Given His Track Record at...
by Barry101 | Dec 2, 2024 | Press Release
Highlights Activist Group’s Nominees’ Checkered Backgrounds, Skewed Incentives and Lack of Independence Warns AIM Shareholders of Activist Group’s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to...
